CARDIMA REGAINS NASDAQ COMPLIANCE

Cardima, developer of the INTELLITEMP and REVELATION series of cardiac interventional systems for the treatment of atrial fibrillation, has received written notice from Nasdaq that the company has regained compliance with Nasdaq Marketplace Rule 4310(c)(2)(B).

The rule requires the company maintain stockholders' equity of not less than $2.5 million, or $35 million market value of listed securities, or $500,000 of net income from continuing operations.

Nasdaq notified Cardima on Nov. 17, 2004, that it did not comply with the minimum requirements of stockholder's equity, or market value of listed securities or net income from continuing operations requirements for the rule. The continued listing of the company's common stock on Nasdaq will depend on the company's continued compliance with all of Nasdaq's listing requirements.